Mei-Ching Liu - Concepedia

Author

Mei-Ching Liu

Koo Foundation Sun Yat-Sen Cancer Center

Also Known As

Mei-Ching Liu

Publications

8.1K

Citations

H-Index

Concepts

All Affiliations

Koo Foundation Sun Yat-Sen Cancer Center Samsung Medical Center National Yang Ming Chiao Tung University Roche (United Kingdom)Seoul National University Hospital

About

Mei-Ching Liu is an author at Koo Foundation Sun Yat-Sen Cancer Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	4.4K
2	Immunology	2	2	3.1K
3	Health Sciences	1	1	168
4	Endocrinology	1	1	973
5	Obstetrics	1	1	973

Mei-Ching Liu

Publications

7.5K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Trastuzumab in HER2-Positive Breast Cancer Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, New England Journal of Medicine	2011	2.7K
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, The Lancet Oncology Breast OncologyOncologyImmunologyBreast CancerCancer Treatment	2011	2.3K
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Debu Tripathy, Seock‐Ah Im, Marco Colleoni, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyEndocrine OncologyMedicine	2018	973
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, The Lancet Oncology 5-Year AnalysisBreast OncologyMedicineRandomised TrialImmunology	2016	846
Interpretation of Magnetic Resonance Imaging for Locally Advanced Rectal Carcinoma After Preoperative Chemoradiation Therapy Li‐Jen Kuo, Ming-Chih Chern, Mei-Hua Tsou, Diseases of the Colon & Rectum	2004	176
Is Final TNM Staging A Predictor for Survival in Locally Advanced Rectal Cancer after Preoperative Chemoradiation Therapy? Li‐Jen Kuo, Mei-Ching Liu, James Jer‐Min Jian, Annals of Surgical Oncology Final TnmA PredictorPreoperative Chemoradiation TherapyCancer RecurrenceMedicine	2007	168
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer Giampaolo Bianchini, Astrid Kiermaier, Giulia Bianchi, Breast Cancer Research	2017	122
Locoregional failure of postmastectomy patients with 1–3 positive axillary lymph nodes without adjuvant radiotherapy Jason Chia‐Hsien Cheng, Chii-Ming Chen, Mei-Ching Liu, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyLocoregional FailureRadiation TherapyMedicineSurgery	2002	73
How aggressive should we be in patients with stage iv colorectal cancer? Li‐Jen Kuo, Shuh-Yan Leu, Mei-Ching Liu, Diseases of the Colon & Rectum	2003	57
Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study Heather‐Jane Au, W. Eiermann, Nicholas J. Robert, The Oncologist	2013	26

Page 1